[Therapy of organic psychosyndromes of cerebrovascular origin with a vasoactive drug combination].
Concrete cross-sectional studies of the organic brain syndrome, carried out periodically, attempt to establish for the parameters evaluation of substrate damage--and different noopsychopathological rating-scales for the measurement of brain capacity impairment. Beyond the level of the purely correlative-statistical point of view of the relationship between parameter and score changes, demanding for a quantitative model which could provide not only a description, but also an explanation for such a relationship. The fact that there can only be a question here of a "quantitative causality" embracing non-specificity of toxic substances and relative to acute and chronic diffuse organic brain syndromes. It results, that quantitative causality meets the requirements of an exponential function model and that one can validate such models through correlative-statistical methods. This has already been carried out by Ball and Taylor.
D000328:Adult; D000368:Aged; D002561:Cerebrovascular Disorders / Q000150:complications*; D004087:Dihydroergotamine / Q000627:therapeutic use*; D004088:Dihydroergotoxine / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D019965:Neurocognitive Disorders / Q000188:drug therapy* / Q000209:etiology; D011581:Psychological Tests; D046948:Secologanin Tryptamine Alkaloids; D012647:Self-Assessment; D015016:Yohimbine / Q000627:therapeutic use*
D004338:Drug Combinations; D046948:Secologanin Tryptamine Alkaloids; C012868:dihydroergotamine, dihydroergotoxine drug combination; D004088:Dihydroergotoxine; D015016:Yohimbine; D004087:Dihydroergotamine; C005709:raubasine
Therapie von organischen Psychosyndromen zerebrovaskulärer Genese mit einem vasoaktiven Kombinationspräparat.